SCHEMBL4093150

SCHEMBL4093150

CC(=O)c1cc(C(=O)Cl)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.47
CDC25B P30305 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
AKR1C3 P42330 13/20 0.45
AKR1C2 P52895 13/20 0.45
AKR1B10 O60218 2/20 0.42
AKR1B1 P15121 2/20 0.42
AKR1C4 P17516 2/20 0.42
AKR1C1 Q04828 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MYC P01106 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4623645 0.90 MAPT (0.40) L3MBTL1AKR1C3AKR1C2AKR1B10AKR1B1
SCHEMBL4613753 0.88 HSD17B10 (0.59) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL4623376 0.86 AKR1C3 (0.57) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL15507330 0.86 KDM4E (0.60) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL8306753 0.86 CDC25B (0.52) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL19329021 0.84 KDM4E (0.58) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL11951528 0.84 POLB (0.63) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL11704191 0.82 HSD17B10 (0.52) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL11951520 0.81 POLB (0.65) CDC25ACDC25BHSD17B10TDP1POLB
SCHEMBL12300194 0.81 CDC25A (0.47) CDC25ACDC25BHSD17B10TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069288-A1 Novel therapeutic compounds MAP3K20, RPS6KB1, MAP3K1 CDC25A 396/4885CDC25B 660/4885HSD17B10 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.